☆ 4.1 Review

Recommendations for the diagnosis and treatment of patients with early breast cancer: update 2023

CURRENT OPINION IN OBSTETRICS & GYNECOLOGY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial

C. E. Geyer et al.

Summary: This study demonstrates that the addition of carboplatin to neoadjuvant chemotherapy can improve the pathological complete response rates in patients with triple-negative breast cancer without increasing the risk of side effects or secondary malignancies.

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Review Oncology

Comparative effectiveness of different localization techniques for non-palpable breast cancer. A systematic review and network meta-analysis

Christos Athanasiou et al.

Summary: This study compared the effectiveness of various localization techniques for non palpable breast cancer. The results showed that ultrasound guided surgery (UGS) had significant advantages over wire localization technique (WGL) in terms of positive margin, re-operation rate, and operative time. UGS also demonstrated a reduction in positive margin compared to radio-guided occult lesion localization (ROLL) and radioactive seed localization (RSL). Other techniques showed similar effectiveness to UGS in successful excision, localization complications, operative time, and overall complications. Further randomized trials are needed to confirm these results.

EJSO (2022)

添加到收藏夹

Article Oncology

Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)

Michael Gnant et al.

Summary: The addition of adjuvant palbociclib to standard endocrine therapy did not improve outcomes over endocrine therapy alone in patients with early hormone receptor-positive breast cancer.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Medicine, General & Internal

Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer

P. Schmid et al.

Summary: The addition of pembrolizumab to neoadjuvant chemotherapy followed by adjuvant pembrolizumab after surgery significantly prolonged event-free survival in patients with early triple-negative breast cancer.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Oncology

Preservation of Axillary Lymph Nodes Compared with Complete Dissection in T1-2 Breast Cancer Patients Presenting One or Two Metastatic Sentinel Lymph Nodes: The SINODAR-ONE Multicenter Randomized Clinical Trial

Corrado Tinterri et al.

Summary: The SINODAR-ONE trial aimed to assess whether SLN biopsy only would worsen the prognosis compared with ALND in patients with T1-2 breast cancer and one or two macrometastatic SLNs. The results showed that the 3-year survival and relapse rates of patients treated with SLNB only were not inferior to those treated with ALND.

ANNALS OF SURGICAL ONCOLOGY (2022)

添加到收藏夹

Article Medicine, General & Internal

Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer

J. Cortes et al.

Summary: Among patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane, trastuzumab deruxtecan was associated with a lower risk of disease progression or death compared to trastuzumab emtansine. However, treatment with trastuzumab deruxtecan was associated with interstitial lung disease and pneumonitis.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Oncology

Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study.

Shanu Modi et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Review Acoustics

Intraoperative Ultrasound-Guided Excision of Non-Palpable and Palpable Breast Cancer: Systematic Review and Meta-Analysis

Maggie Banys-Paluchowski et al.

Summary: Wire-guided localization (WGL) is commonly used for non-palpable breast cancer (BC), but has potential disadvantages. Intraoperative ultrasound (IOUS)-guided excision is a safe and effective alternative that improves negative margin rates and reduces re-operation rates, especially for non-palpable BC.

ULTRASCHALL IN DER MEDIZIN (2022)

添加到收藏夹

Article Oncology

Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study

N. Harbeck et al.

Summary: Adjuvant abemaciclib combined with endocrine therapy significantly improved invasive disease-free survival in patients with early breast cancer, with an acceptable safety profile. Ki-67 index was prognostic but did not affect the benefits of abemaciclib. The robust treatment benefit of abemaciclib extended beyond the planned 2-year treatment period.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Review Oncology

False Negativity of Targeted Axillary Dissection in Breast Cancer

George Kirkilesis et al.

Summary: The false-negative rate of TAD is typically reported to be less than 10%, but this calculation is often based on small study populations. Lower FNR is commonly associated with lower N status, while there is insufficient data for greater axillary involvement yet.

BREAST CARE (2021)

添加到收藏夹

Article Oncology

Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study

Erica L. Mayer et al.

Summary: The PALLAS trial investigated whether adding 2 years of palbociclib to adjuvant endocrine therapy could improve invasive disease-free survival in early-stage hormone-receptor-positive, HER2-negative breast cancer patients, but the results showed no significant benefit. The trial was then discontinued based on the lack of efficacy observed during the planned second interim analysis.

LANCET ONCOLOGY (2021)

添加到收藏夹

Review Oncology

Moderate hypofractionation remains the standard of care for whole-breast radiotherapy in breast cancer: Considerations regarding FAST and FAST-Forward

David Krug et al.

Summary: Moderate hypofractionation is the standard of care for adjuvant whole-breast radiotherapy after breast-conserving surgery for breast cancer. Ultra-hypofractionated regimens have shown non-inferiority in terms of local control, but at the cost of elevated rates of late toxicity. Differences in late effects between standard and experimental arms were evident, with experimental arms showing worse outcomes in some cases.

STRAHLENTHERAPIE UND ONKOLOGIE (2021)

添加到收藏夹

Article Oncology

Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors- An analysis of 2765 patients from neoadjuvant clinical trials

Sonia L. Villegas et al.

Summary: The study found that patients with low hormone receptor expression HER2-negative breast cancer had similar treatment response and survival rates as patients with triple-negative breast cancer, while patients with strong hormone receptor-positive breast cancer had a lower pathological complete response rate but better survival rates. Low hormone receptor expression breast cancer patients were predominantly classified into a basal-like subtype based on gene expression analysis.

EUROPEAN JOURNAL OF CANCER (2021)

添加到收藏夹

Article Oncology

Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial

Sibylle Loibl et al.

Summary: The study investigated the efficacy of palbociclib in breast cancer patients with residual invasive disease after neoadjuvant chemotherapy, showing that palbociclib in addition to endocrine therapy did not improve invasive disease-free survival. Some related serious adverse events were reported, but no significant difference between treatment arms.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

De-escalated neoadjuvant pertuzumab+trastuzumab with or without paclitaxel weekly in HR-/HER2+ early breast cancer: ADAPT-HR-/HER2+ biomarker and survival results.

Nadia Harbeck et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer

Andrew N. J. Tutt et al.

Summary: In patients with high-risk, HER2-negative early breast cancer and germline BRCA1 or BRCA2 pathogenic or likely pathogenic variants, adjuvant olaparib after completion of local treatment and neoadjuvant or adjuvant chemotherapy was associated with significantly longer survival free of invasive or distant disease than placebo. Olaparib had limited effects on global patient-reported quality of life.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Oncology

Preexisting Somatic Mutations of Estrogen Receptor Alpha (ESR1) in Early-Stage Primary Breast Cancer

Malin Dahlgren et al.

Summary: The study found that about 1% of patients with primary breast cancer have ESR1 gene mutations, which may be associated with resistance to standard hormone therapy. It is suggested that screening for ESR1 mutations should be considered in ER-positive breast cancer, and treatment options such as ER degraders may be more appropriate for patients with mutations.

JNCI CANCER SPECTRUM (2021)

添加到收藏夹

Review Oncology

DEGRO practical guideline for partial-breast irradiation

V. Strnad et al.

STRAHLENTHERAPIE UND ONKOLOGIE (2020)

添加到收藏夹

Article Surgery

Extended Prophylactic Antibiotics for Mastectomy with Immediate Breast Reconstruction: A Meta-analysis

Yang Hai et al.

PLASTIC AND RECONSTRUCTIVE SURGERY-GLOBAL OPEN (2020)

添加到收藏夹

Article Medicine, General & Internal

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

G. von Minckwitz et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Article Infectious Diseases

Analysis of clinical management of infected breast implants and of factors associated to successful breast pocket salvage in infections occurring after breast reconstruction

Simonetta Franchell et al.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2018)

添加到收藏夹

Article Oncology

Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial

Sibylle Loibl et al.

LANCET ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled, phase 3 trial

Viviana Galimberti et al.

LANCET ONCOLOGY (2018)

添加到收藏夹

Article Surgery

Association of Low Nodal Positivity Rate Among Patients With ERBB2-Positive or Triple-Negative Breast Cancer and Breast Pathologic Complete Response to Neoadjuvant Chemotherapy

Alison U. Barron et al.

JAMA SURGERY (2018)

添加到收藏夹

Article Medicine, General & Internal

Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis The ACOSOG Z0011 (Alliance) Randomized Clinical Trial

Armando E. Giuliano et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)

添加到收藏夹

Article Medicine, General & Internal

Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy

N. Masuda et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Article Oncology

Utility of the CPS plus EG staging system in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with neoadjuvant chemotherapy

Frederik Marme et al.

EUROPEAN JOURNAL OF CANCER (2016)

添加到收藏夹

Article Oncology

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

Massimo Cristofanilli et al.

LANCET ONCOLOGY (2016)

添加到收藏夹

Article Multidisciplinary Sciences

Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection

Brian D. Lehmann et al.

PLOS ONE (2016)

添加到收藏夹

Article Oncology

Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques

Joerg Heil et al.

BRITISH JOURNAL OF CANCER (2015)

添加到收藏夹

Article Oncology

Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831

Edith A. Perez et al.

JOURNAL OF CLINICAL ONCOLOGY (2014)

添加到收藏夹

Article Medicine, Research & Experimental

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

Brian D. Lehmann et al.

JOURNAL OF CLINICAL INVESTIGATION (2011)

添加到收藏夹

Article Oncology

Validation of a Novel Staging System for Disease-Specific Survival in Patients With Breast Cancer Treated With Neoadjuvant Chemotherapy

Elizabeth A. Mittendorf et al.

JOURNAL OF CLINICAL ONCOLOGY (2011)

添加到收藏夹

Article Medicine, General & Internal

Adjuvant Trastuzumab in HER2-Positive Breast Cancer

Dennis Slamon et al.

NEW ENGLAND JOURNAL OF MEDICINE (2011)

添加到收藏夹

Review Surgery

Capsular Contractures: A Systematic Review

Antonino Araco et al.

PLASTIC AND RECONSTRUCTIVE SURGERY (2009)

添加到收藏夹

Article Medicine, General & Internal

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial

Ian Smith et al.

LANCET (2007)

添加到收藏夹

Article Surgery

Textured surface breast implants in the prevention of capsular contracture among breast augmentation patients: A meta-analysis of randomized controlled trials

GP Barnsley et al.

PLASTIC AND RECONSTRUCTIVE SURGERY (2006)

添加到收藏夹

Article Medicine, General & Internal

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

MJ Piccart-Gebhart et al.

NEW ENGLAND JOURNAL OF MEDICINE (2005)

添加到收藏夹

Article Medicine, General & Internal

Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer

U Veronesi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2002)

添加到收藏夹

Article Medicine, General & Internal

Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation

B Fisher et al.

NEW ENGLAND JOURNAL OF MEDICINE (2002)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.